AstraZeneca Updates MYSTIC Plan In Bid To Challenge Merck In NSCLC

With tensions rising in the first-line NSCLC space, AstraZeneca's update on the analysis plan of its Phase III MYSTIC trial has analysts reassessing the firm’s chances against stiff competition.

T-cells attacking cancer_1200x675

AstraZeneca PLC's revisions to its MYSTIC trial evaluating its anti-PD-L1 durvalumab and anti-CTLA-4 tremelimumab in first-line non-small cell lung cancer (NSCLC) should expand the scope of what is possible with the trial, but it now runs the risk of being underpowered.

The new plan places slightly more emphasis on durvalumab as a monotherapy, despite AstraZeneca stating: "the focus remains on exploring...

More from Immuno-oncology

More from Anticancer

Will AstraZeneca Reach Summit And Be A PD-1xVEGF Player?

 
• By 

Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.

Dizal’s Zegfrovy Wins US NSCLC Approval, At Lower Dose Than In China

 

Dizal's EGFR inhibitor Zegfrovy approved in US as new once-daily oral option for second-line NSCLC with EGFR exon 20 insertion mutations, at lower dose than in China.

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.